<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696031</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457H2315</org_study_id>
    <nct_id>NCT02696031</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab to Evaluate the Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Non-radiographic Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to
      placebo in patients with non-radiographic axial spondyloarthritis at Week 16 as well as week
      52 and long term efficacy and safety up to Week 104.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who achieved an ASAS 40 response (Assessment of SpondyloArthritis International Society criteria)</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS40 (Assessment of SpondyloArthritis International Society criteria) response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants who achieved an ASAS 40 response (Assessment of SpondyloArthritis International Society criteria)</measure>
    <time_frame>Week 52</time_frame>
    <description>ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who achieved an ASAS 5/6</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) over time</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 (Short Form-36 Physical Component Summary) physical Component Summary over time</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>The SF-36 (Short Form-36 Physical Component Summary) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients to achieve a BASDAI 50 response</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sacroiliac Joint Edema</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>MRI assessment of the Sacroiliac Joint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C-reactive protein over time</measure>
    <time_frame>Week 16</time_frame>
    <description>high sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who achieved an ASAS 20 response</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BASFI (Bath Ankylosing Spondylitis Functional Index) over time</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASFI (Bath Ankylosing Spondylitis Functional Index) is a set of 10 questions designed to determine the degree of functional limitation in those patients with AS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who achieved an ASAS partial remission</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">555</enrollment>
  <condition>Non-radiographic Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c. no load</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>150 mg Secukinumab s.c. monthly</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-nursing female patients at least 18 years of age

          -  Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis
             International Society (ASAS) axial spondyloarthritis criteria

          -  objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal
             C-reactive protein)

          -  active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis
             Disease Activity Index &gt;=4 cm

          -  Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index
             question #2 ≥ 4 cm (0-10 cm) at baseline

          -  Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline

          -  Patients should have been on at least 2 different non-steroidal anti-inflammatory
             drugs with an inadequate response

          -  Patients who have been on a TNFα inhibitor (not more than one) must have experienced
             an inadequate response

        Exclusion Criteria:

          -  Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade
             ≥ 3 unilaterally

          -  Inability or unwillingness to undergo MRI

          -  Chest X-ray or MRI with evidence of ongoing infectious or malignant process

          -  Patients taking high potency opioid analgesics

          -  Previous exposure to secukinumab or any other biologic drug directly targeting
             interleukin-17 (IL-17) or IL-17 receptor

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1060</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottbus</city>
        <zip>03042</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>October 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-radiographic spondyloarthritis</keyword>
  <keyword>axial spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
